Baricitinib in the Treatment of a Critical Patient with COVID-19 Pneumonia: a case report
The author(s) received no specific funding for this work.
A 72-year-old male presented to the emergency department with a chief complaint of diarrhea after having tested positive for COVID-19 two days prior. He initially had minimal respiratory complaints, but was eventually transferred to the intensive care unit for acute hypoxic respiratory failure. In addition to dexamethasone, remdesivir, and antibiotics, the patient was treated with baricitinib, a Janus kinase inhibitor that was recently granted emergency use authorization by the Food and Drug Administration for treatment of hospitalized patients with COVID-19. He had an extensive and complicated hospital course and had to be placed on mechanical ventilation, ultimately undergoing tracheostomy. After 78 days of hospitalization, his family withdrew life-sustaining measures and the patient died shortly thereafter. This case details the use of baricitinib for treatment of COVID-19 pneumonia, and demonstrates the need for additional studies regarding the efficacy of this drug.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Patel, Nishant; Goldsmith, Dylan; and Arnold, Forest W.
"Baricitinib in the Treatment of a Critical Patient with COVID-19 Pneumonia: a case report,"
The University of Louisville Journal of Respiratory Infections: Vol. 5
, Article 18.
Available at: https://ir.library.louisville.edu/jri/vol5/iss1/18
Hospital day 1: Patchy right infrahilar opacities concerning for pneumonia and/or atelectasis
1200figure1b.jpg (31 kB)
Hospital day 4: Interval worsening of the bilateral patchy airspace opacities
Epidemiology Commons, Infectious Disease Commons, International Public Health Commons, Medical Pharmacology Commons, Medical Toxicology Commons, Pulmonology Commons, Virus Diseases Commons